Choose combos that match your playing style and switch them in the heat of battle to bring your enemies to their knees. Use up to 2 skulls at a time, each of which has its own unique attack range, speed, and power. In addition to his formidable fighting skills, he can gain new and exciting abilities depending on which skull he’s wearing. It will keep you on your toes, as you will never know what to expect. ‘Skul: The Hero Slayer’ is an action-platformer that boasts rogue-like features such as ever-changing and challenging maps. Becoming partners with NEOWIZ was one of the best things to happen to our little Skul.” SouthPAW Games CEO Sangwoo Park said, “By working with Neowiz in promotion, marketing, QA, and user-communication, we were able to focus on developing Skul to ensure that the final product was something we could be proud to call our own. “We’ll continue doing our best to bring quality games to users all over the world.” “It is very meaningful to be recognized by fans internationally,” said Seungchul Kim, CEO of NEOWIZ. To commemorate this incredible achievement, Skul: The Hero Slayer will be on sale from January 27th through February 3rd, 2022 for 35% off – its steepest discount on Steam to date! As the first Korean-packaged indie game to sell 1 million copies, Skul sold 100,000 copies just 5 days after it was officially released on Steam in January 2021, and has continued to wow players the world over. Recently, Skul: The Hero Slayer was also announced as one of the 12 games in Steam’s Platinum Tier for Early Access Graduates in 2021. With an over 90% approval rating on Steam, Skul has become one of the highest-selling roguelite games alongside contemporaries like Hades and Dead Cells. Skul: The Hero Slayer, the smash hit roguelite 2D platformer published by NEOWIZ and developed by SouthPAW Games, is pleased to announce that it has now sold over one million copies globally across platforms. The little skeleton-that-could joins one of 12 top-selling Early Access graduates from 2021’s Steam Awards
0 Comments
Leave a Reply. |